Journal of Clinical Oncology
Articles in this Issue
Belantamab treatment of multiple myeloma: Results from part 1 of the first-in-human phase 1/2 DREAMM-20 trial.
7550 Background: Belantamab mafodotin (belamaf) is a B-cell maturation antigen (BCMA)–targeted monoclonal antibody (mAb) conjugated with a monomethyl auri...
Comparative effectiveness of CAR-T cell therapy and BiTE therapy in relapsed/refractory diffuse large B-cell lymphoma: A propensity score matching analysis using real-world data from the US collaborative network database.
e19020 Background: Diffuse Large B-cell lymphoma is the most common form of non-Hodgkin lymphoma. Relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL...
Using live true single-circulating tumor cell comprehensive genomics to show clonal evolution and tumor heterogeneity in pancreatic cancer management.
4164 Background: Traditional tissue and CtDNA biopsies have limitations in pancreatic ductal adenocarcinoma (PDAC) due to sampling bias and inability to c...
Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM).
7507 Background: CARTITUDE-1 evaluated cilta-cel in pts with heavily pretreated RRMM who historically have an expected median progression-free survival (P...
Clinical application of the PainVision system for quantitative assessment of chemotherapy-induced peripheral neuropathy.
e24038 Background: Chemotherapy is one of the important methods of anti-tumor treatment at present. It brings disease remission along with various adverse...
mFOLFIRINOX efficacy as rescue regimen for patients with metastatic refractory colorectal cancer: The RE-PLAY trial.
3554 Background: Doublets with Fluoropyrimidines (F), oxaliplatin (Ox), and irinotecan (Ir) are standard chemotherapy agents used to treat metastatic colo...
Pilot study of intestinal microbiome alteration with resistant potato starch (RPS) in patients (pts) treated with dual immune checkpoint inhibitors (ICI).
e24120 Background: The intestinal microbiome is associated with ICI efficacy & toxicity; whether it can be altered to improve clinical outcome is unkn...
Advancing precision oncology in soft tissue sarcomas: The role of iTRAC in metastatic risk stratification and treatment personalization.
11534 Background: Soft Tissue Sarcomas (STS), known for their extensive Genomic instability (GIN), often result in poor clinical outcomes. Grading systems...
Racial disparities in major adverse cardiovascular and cerebrovascular events outcomes among gastric cancer patients.
11070 Background: Racial disparities in healthcare outcomes represent a critical challenge in achieving equity in gastric cancer care. Gastric cancer, oft...
Profiling DNA damage response in ATM/BRCA2 carriers to inform hereditary cancer risk.
10574 Background: Approximately 10% of cancers stem from inherited germline pathogenic variants (gPV), predominantly in DNA repair genes including...
Real-world comparison of lutetium-177 vipivotide tetraxetan in advanced castration resistant metastatic prostate cancer patients in Appalachia.
e17026 Background: Patients (pts) with advanced metastatic castration resistant prostate cancer (mCRPC) have undergone multiple modalities of therapy limi...
Adjuvant abemaciclib outcomes in routine clinical practice (experience of several Moscow centers).
e12522 Background: Adjuvant abemaciclib (aA) combined with endocrine therapy (ET) is one of standard treatment for HR+/HER2- early breast cancer (BC). Whi...
A phase 1b study of Plk1 inhibitor onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) patients.
1100 Background: TNBC represents 15-20% of all breast cancer and is characterized by a more aggressive clinical course compared to other subtypes with res...
Automated conversational artificial intelligence (AI) for outpatient malignant bowel obstruction (MBO) symptom monitoring.
1547 Background: MBO is a severe complication of advanced cancer. A Canadian ambulatory MBO program with nurse-led proactive call management demonstrated...
Recurrence-free survival dynamics following adjuvant chemotherapy for resected non-colorectal cancers of the gastrointestinal tract: A systematic review of randomized controlled trials.
e16181 Background: Adjuvant cytotoxic chemotherapies can improve recurrence-free survival (RFS) for a range of gastrointestinal malignancies. By previous...
A situational analysis of pediatric cancer diagnostic and research capacity at two childhood cancer treatment centers in Accra, Ghana.
e13774 Background: Despite being crucial for effective treatment selection, access to diagnostics in pediatric oncology remains deficient and inequitable...
Preliminary results of a phase 1 study of LB1908, an autologous Claudin 18.2–targeted chimeric antigen receptor T-cell product, in patients with advanced gastroesophageal adenocarcinoma.
4022 Background: Claudin 18.2 (CLDN18.2) is a potential therapeutic target expressed on most gastric, gastroesophageal, and esophageal adenocarcinomas (GC...
Pain attribution and management in non-aggressive bone tumors.
e23502 Background: Non-aggressive bone tumors represent approximately 50-60% of surgically treated bone tumors. While osteoid osteomas and chondroblastoma...
Enhancing care of patients with HR+/HER2- early breast cancer at high risk of recurrence through an expansive curriculum: Real world outcomes (RWO) from a 6 month analysis.
e12509 Background: Although therapies for patients with HR+/HER2- early breast cancer have been available for several years, a number of clinical gaps rem...
A retrospective pilot study of neoadjuvant chemotherapy combined with immunotherapy in the treatment of thoracic esophageal squamous cell carcinoma with cervical lymph node metastasis.
e16000 Background: Esophageal squamous cell carcinoma (ESCC) with cervical lymph node metastasis (CLNM) has a poor prognosis. Guidelines recommend chemoth...
Implementation of a clinical trial navigation program for cancer patients: Barriers and facilitators identified through stakeholder perspectives.
1608 Background: Patient navigation has been highlighted as a solution to improve clinical trial access. The Clinical Trial Navigator (CTN) Program is a C...
Preliminary results from a first-in-human, phase I/II study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced solid tumors.
3012 Background: VLS-1488 is an oral small molecule inhibitor of KIF18A, a mitotic kinesin protein important for successfu...
The landscape ecology of DCIS: Microenvironmental drivers of recurrence and progression to breast cancer.
e12568 Background: Modern preventive screening have made it possible to identify ductal carcinoma in situ (DCIS). Progression of DCIS to invasive disease...
SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study.
4093 Background: Combination of an anti-PD-1/L1 antibody with an anti-angiogenic agent is currently the preferred 1L treatment for aHCC. Addition of a CTL...
The Pareto principle in oncology: How a minority of countries account for the major share of Latin American contributions to ASCO Annual Meetings.
e23111 Background: Latin America (LA), with a population of 659 million people (8.2% of the global total), is seeing cancer become one of the leading caus...